COVID-19 Anosmia Study

ID#: NCT04495816

Age: 18 years - 66+

Gender: Female

Healthy Subjects: No

Study Phase: Phase 2

Recruitment Status: Recruiting

Start Date: July 15, 2020

End Date: June 01, 2021

Contact Information:
Alfred-Marc Iloreta, MD
David K Lerner, MD

To capture the natural history of COVID-19 associated olfactory dysfunction as measured by two patient reported outcome measures (SNOT-22, QOD-NS) and a 6-week BSIT with a comparison to an intervention arm receiving daily omega-3 supplements.


Inclusion Criteria:

- Adults (18 years of age or older) with self-reported new-onset olfactory dysfunction

- Positive COVID-19 diagnosis will be deemed eligible for inclusion.

Exclusion Criteria:

- Patients <18 years of age

- Patients who are unable to provide informed consent

- Patients without a positive COVID-19 PCR result obtained through nasopharyngeal swab

- Patients with a COVID-19 diagnosis but without self-reported anosmia

- Patients with severe COVID-19 disease as defined by the Mouth Sinai Health System Treatment Guidelines for SARS-COV-2 (requiring high flow nasal cannula, non-rebreather, CPAP/BIPAP, or mechanical ventilation OR patients requiring pressor medication OR patients with evidence of end organ damage)

- Patients with pre-existing self-reported olfactory dysfunction

- Patients with a history of chronic nasal/sinus infections (rhinosinusitis) or history of endoscopic sinus surgery

- Patients using nasal steroid sprays or irrigations for any reason

- Patients who are prisoners of the state

- Patients who have psychiatric or developmental disorder conditions that may impair ability to provide informed consent

- Patients will also be excluded if they have an allergy to fish or an omega-3 supplement, or do not eat fish or fish- containing substances for any reason